EMA: Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome

This guideline intends to address the EU regulatory position in the main topics of clinical development of new medicinal products in the treatment of patients with Irritable Bowel Syndrome (IBS). It is a revision and expansion of the previous “Points to Consider on the Evaluation of Medicinal Products for the treatment of Irritable Bowel Syndrome”, which has been in operation since the year 2003.